(1 -> 3)-beta-D-Glucan-guided antifungal therapy in adults with sepsis: the CandiSep randomized clinical trial

Bloos F, Held J, Kluge S, Simon P, Kogelmann K, De Heer G, Kuhn SO, Jarczak D, Motsch J, Hempel G, Weiler N, Weyland A, Druener M, Gruendling M, Meybohm P, Richter D, Jaschinski U, Moerer O, Guenther U, Schaedler D, Weiss R, Putensen C, Castellanos AI, Kurzai O, Schlattmann P, Cornely OA, Bauer M, Thomas-Rueddel D (2022)


Publication Type: Journal article

Publication year: 2022

Journal

DOI: 10.1007/s00134-022-06733-x

Abstract

Purpose: To investigate whether (1 -> 3)-beta-d-Glucan (BDG)-guidance shortens time to antifungal therapy and thereby reduces mortality of sepsis patients with high risk of invasive Candida infection (ICI).

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Bloos, F., Held, J., Kluge, S., Simon, P., Kogelmann, K., De Heer, G.,... Thomas-Rueddel, D. (2022). (1 -> 3)-beta-D-Glucan-guided antifungal therapy in adults with sepsis: the CandiSep randomized clinical trial. Intensive Care Medicine. https://doi.org/10.1007/s00134-022-06733-x

MLA:

Bloos, Frank, et al. "(1 -> 3)-beta-D-Glucan-guided antifungal therapy in adults with sepsis: the CandiSep randomized clinical trial." Intensive Care Medicine (2022).

BibTeX: Download